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In Brief 
	
This review discusses the importance of autophagy function for brain health, outlining 
connections between autophagy dysfunction and neurodegenerative disorders. The potential 
for autophagy as a therapeutic strategy for neurodegenerative disease is discussed, along 
with how this may be achieved. 
	
Summary 
 
Autophagy is a conserved pathway that delivers cytoplasmic contents to the 
lysosome for degradation. Here we consider its roles in neuronal health and disease. 
We review evidence from mouse knock-out studies demonstrating the normal 
functions of autophagy as a protective factor against neurodegeneration associated 
with intracytoplasmic aggregate-prone protein accumulation, as well as other roles 
including in neuronal stem cell differentiation. We then describe how autophagy may 
be affected in a range of neurodegenerative diseases. Finally, we describe how 
autophagy upregulation may be a therapeutic strategy in a wide range of 
neurodegenerative conditions and consider possible pathways and druggable targets 
that may be suitable for this objective. 
 
 
Autophagy cel l  biology 
 
Macroautophagy (henceforth autophagy) is a major intracytoplasmic protein degradation 
pathway whereby cytoplasmic contents are delivered, by double-membraned vesicles called 
autophagosomes, to the lysosome for degradation. It should be differentiated from other 
pathways that will not be considered in this review, like chaperone-mediated autophagy and 
microautophagy, where substrates are directly translocated into the lysosome without 
vesicular transport. The first morphologically characteristic structure in autophagy is the 
double-membraned cup-shaped autophagosome precursor called the phagophore that 
engulfs substrates as its edges extend. After the phagophore edges close to form a vesicle, 
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the completed autophagosomes traffic along microtubules to enable autophagosome-
lysosome fusion, which leads to the degradation of the autophagic contents (figure 1). 
Autophagy is regulated by a series of proteins defined as ATG (AuTophaGy-related) 
proteins. 
 
Autophagy was initially characterized as a bulk and non-selective degradation pathway 
induced by nutrient deprivation. However, more recent studies made clear that autophagy 
also contributes to intracellular homeostasis in non-starved cells by degrading cargo 
material, such as aggregate-prone proteins, including those causing many 
neurodegenerative conditions (aggrephagy), damaged mitochondria (mitophagy), excess 
peroxisomes (pexophagy) and invading pathogens (xenophagy) (Stolz et al., 2014). In the 
classic example, aggregates of aberrantly folded proteins are tagged with ubiquitin chains, 
which are recognized by ubiquitin-binding domain-containing receptors, such as 
p62/SQSTM1 (Sequestosome 1) (Bjørkøy	et	al.,	2005), NBR1 (Neighbor Of BRCA1 Gene 1) 
(Kirkin et al., 2009), OPTN (optineurin) (Wild et al., 2011), TAX1BP1 (Tax1 binding protein 
1), NDP52/CALCOCO2 (Nuclear Dot Protein 52 (Newman et al, 2012), TOLLIP (TOLL 
interacting protein) (Lu et al., 2014) and 26S proteasome regulatory subunit (RPN10) 
(Marshall et al., 2015) (Khaminets et al., 2016; Stolz et al., 2014). These receptors also 
contain LIR (LC3-interacting region) motifs in their sequences that can recognize the key 
autophagosome-associated protein, microtubule-associated protein 1 light chain 3 (LC3). 
Thus, these receptors serve as a bridge between ubiquitinated cargo and autophagosomes, 
and enhance the incorporation of cargo into autophagosomes for subsequent lysosomal 
degradation (Bjorkoy et al., 2005; Pankiv et al., 2007).  
 
This concept of selective autophagy has now been extended with the description of precision 
autophagy. This is defined by the involvement of receptors with the ability to recognize LC3 
family member proteins, their specific substrates and also, importantly, the capacity to act as 
platforms for the assembly of other core ATG factors (Kimura et al., 2015). To date, 
receptors identified in this class come from the TRIM family, a diverse group of proteins 
associated with the degradation of targets such as innate immunity signaling molecules 
(reviewed in Kimura et al., 2016). It seems likely that there are many other molecules that 
play such roles in autophagy and identifying them will be key for our understanding of 
autophagy in non-starved cells. 
Key autophagy regulators 
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Autophagy activation in response to the primordial stimuli of nutrient deprivation and/or low 
cellular energy levels is mediated by signalling pathways that converge on ULK1/2 
(mammalian homologs of the C. elegans uncoordinated-51 kinase) (figure 2). ULK1/2 forms 
a complex with ATG13, ATG101 and FIP200 (focal adhesion kinase family interacting 
protein of 200 kD). Nutrients and growth factor availability and levels of AMP/ATP (which 
reflect the energetic status of the cell) are sensed by mammalian target of rapamycin 
complex 1 (mTORC1) and AMP-dependent protein kinase (AMPK), respectively, which, in 
turn, oppositely regulate the ULK1/2 complex through a series of phosphorylation events. 
For instance, activation of AMPK by allosteric binding of AMP and phosphorylation of Thr172 
promotes autophagy by directly activating ULK1 through phosphorylation of Ser 317 and 
Ser77 under glucose deprivation (Kim et al., 2011), or Ser 555 under amino acid starvation 
and mitophagy (Egan et al., 2011). On the other hand, in media replete with amino acids 
(sensed by the Rag-Ragulator complex) and growth factors (that signal by receptor tyrosine 
kinases and the PI3K/AKT pathway), mTORC1 is activated and inhibits autophagy by 
binding to the ULK1 complex (via Raptor-ULK1 interaction), and by phosphorylating both 
ATG13 and ULK1 (at Ser 757), thereby suppressing ULK1 kinase activity and preventing the 
interaction between ULK1 and AMPK (Ganley et al., 2009; Hosokawa et al., 2009; Jung et 
al., 2009; Laplante and Sabatini, 2012).  
 
Activation of the ULK complex is required for the recruitment of the class III PI 3-kinase, 
VPS34, to the phagophore initiation sites where VPS34 generates phosphatidylinositol 3-
phosphate (PI3P), while in a complex with VPS15, ATG14 and Beclin 1.The exact functions 
of PI3P in autophagy are still unclear. However, it appears to aid the recruitment of WD 
repeat domain phosphoinositide-interacting (WIPI) proteins to the phagophore membrane, 
which, in turn, control the recruitment of crucial downstream autophagic proteins (e.g., 
ATG16L1 by WIPI2) that dictate where the phagophores form (Dooley et al., 2014).  
 
The ATG12 and ATG8/LC3 ubiquitin-like conjugation systems are then required for 
sustaining the expansion of the phagophore. In the first system, ATG12 is conjugated to 
ATG5, in a reaction that involves ATG7 and ATG10 (E1-like and E2-like enzymes, 
respectively), and the resulting complex binds non-covalently to ATG16L1. ATG12-ATG5-
ATG16L1 associates with pre-autophagosomal membranes enabling their elongation by 
assisting in the recruitment of LC3. However, before this can happen, LC3 has to be 
processed by the cysteine protease ATG4 that cleaves the C-terminus of LC3 exposing a 
glycine residue (LC3-I form). This cleavage is crucial for LC3-I conjugation to 
phosphatidylethanolamine (PE), by a mechanism dependent on ATG7, ATG3 and ATG12-
ATG5-ATG16L1 (E1-like, E2-like and E3-like enzymes, respectively), leading to the 
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formation of LC3-II, which is tightly associated with autophagosomal membranes. This 
cascade of reactions then sustains extension of the phagophore edges and its closure, to 
form mature autophagosomes (Bento et al., 2016b).    
 
Extension of the phagophore is also assisted by mATG9, the only identified multi-pass 
transmembrane protein among the core ATG proteins. This protein appears to localize to the 
trans-Golgi network and the endocytic compartment, including early endosomes, late 
endosomes and recycling endosomes, and is postulated to aid in the supply of lipid-bilayers 
to the nascent phagophore, enabling its further elongation, prior to closure of the fully formed 
autophagosome (Bento et al., 2016b). This late stage, where the outer and the inner 
membranes of the pre-autophagosomal structure become separate entities, is poorly 
understood, but ATG2 in combination with WIPI1 appear to regulate autophagosome closure 
(Velikkakath et al., 2012), a process likely involving  membrane fission/scission type events 
akin to  the genesis of multi-vesicular bodies by ESCRT (endosomal sorting complexes 
required for transport)-mediated membrane budding (Knorr et al., 2015).         
 
The source of autophagosome membranes is an area of active investigation. Endoplasmic 
reticulum (ER), Golgi and trans-Golgi network, mitochondria, plasma membrane and 
endosomal compartments have all been suggested as possible sources of phagophore-
membranes (Bento et al., 2016b). The ER emerged as one of the possible sources of 
membrane for pre-autophagosomes not only because isolation membranes were observed 
cradled within a subdomain of the ER and interconnected with it (Axe et al., 2008; Hayashi-
Nishino et al., 2009), but also because ATG14- and ATG5-positive isolation membranes 
were found in close proximity to a subdomain of the ER in contact with mitochondria during 
starvation (Hamasaki et al., 2013). Post-Golgi tubulo-vesicular compartments undergoing 
remodelling and homotypic fusion (Guo et al., 2012; Orsi et al., 2012; Young et al., 2006), 
and the ER-Golgi intermediate compartment (ERGIC) have also been considered as pre-
autophagosomal membrane sources (Ge et al., 2013; Ge et al., 2014). The ERGIC was 
specifically observed to bud LC3-lipidation active vesicles that may enable autophagosome 
biogenesis and expansion (Ge et al., 2013; Ge et al., 2014).  
 
The plasma membrane and the endocytic compartments are also suggested as membrane 
sources for early autophagosomal-precursor structures. Clathrin-dependent endocytosis has 
been implicated in this process by delivering ATG16L1 and mATG9 to recycling endosomes 
(via different routes and involving VAMP3-dependent membrane fusion events), which leads 
to the formation of early autophagosomal structures and mature autophagosomes (Moreau 
et al., 2011; Puri et al., 2013; Ravikumar et al., 2010). Over-expression of the recycling 
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endosome proteins TBC1D14 (a Rab11-effector) or PX-containing SNX18 were shown to 
induce accumulation of mATG9 and ATG16L1, respectively, along with other autophagic 
proteins (e.g., ULK1 and LC3) in this compartment (Knaevelsrud et al., 2013; Lamb et al., 
2016; Longatti et al., 2012), reinforcing the possible role of recycling endosome as an 
important phagophore-membrane source.  
Transcriptional regulation of autophagy 
In addition to phosphorylation, discussed above, autophagy is also regulated at the 
transcriptional level. mTORC1, apart from regulating the ULK1/2 complex, also connects the 
lysosome nutrient-sensing (LYNUS) machinery to the transcriptional regulation of autophagy 
genes via transcription factor EB (TFEB) (Settembre et al., 2012). In resting cells, 
phosphorylation of TFEB by active mTORC1 induces TFEB binding to 14-3-3 proteins and 
therefore TFEB retention in the cytosol (Roczniak-Ferguson et al., 2012; Settembre et al., 
2011). However, under starvation and consequent mTORC1 inactivation, TFEB is no longer 
phosphorylated and translocates to the nucleus, where it binds to CLEAR (Coordinated 
Lysosomal Expression and Regulation) consensus sequences in promoters of target genes 
and induces their transcription. Among these genes, many are directly related to the 
lysosome and autophagy (e.g. lysosomal hydrolases, vATPase subunits, ATG proteins) and 
thus TFEB appears to co-ordinately regulate the expression of many of the key genes 
required for autophagy/lysosome function (Sardiello et al., 2009; Settembre et al., 2011). 
ZKSCAN3 (zinc-finger protein with KRAB and SCAN domains 3) is a transcriptional 
repressor of autophagy that appears to oppose TFEB. ZKSCAN3 silencing enhances 
autophagosome and lysosomal biogenesis, and mTORC1 inhibition induces its accumulation 
in the cytosol (Chauhan et al., 2013). More than 20 other transcription factors have now 
been linked to transcriptional regulation of autophagy following a wide range of stimuli 
(Fullgrabe et al., 2014). For instance, microphthalmia-associated transcription factor (MITF) 
(which belongs to the same family of proteins as TFEB) (Martina et al., 2014), p53 
(Kenzelmann Broz and Attardi, 2013) and forkhead box O3 (FOXO3) (Mammucari et al., 
2007) have all been shown to trans-activate ATG genes.   
 
Autophagy physiology and the nervous system  
	
The mammalian nervous system requires autophagy to maintain its normal functions and 
homeostasis. Since ubiquitous deletion of core autophagy genes results in neonatal and 
embryonic lethality, multiple nervous system-specific knock-out mouse models have been 
generated to allow analyses of the roles of autophagy in neuronal function. A Nestin-Cre 
7	
	
promoter, that switches on embryonically in neuronal precursor cells has been used to 
excise floxed alleles of Atg5 and Atg7. This results in autophagy deficiency in neuronal cells 
and glia accompanied by the accumulation of intra-neuronal aggregates (Hara et al., 2006; 
Komatsu et al., 2006; Komatsu et al., 2007a). The accumulation of these aggregates in 
otherwise normal mice suggests that autophagy plays a key role in removing aggregate-
prone proteins, supporting earlier studies in cell culture models of Huntington’s disease 
(Ravikumar et al., 2002). Subsequent Nestin-Cre models have been generated targeting 
FIP200 and Wipi4 as well as a double-knockout for Ulk1/2 (Joo et al., 2016; Liang et al., 
2010; Orosco et al., 2014). The result in all models is reduced survival, and early onset, 
progressive neurodegeneration across broad areas of the brain. However, the nature of 
pathology varies according to the gene targeted e.g. progressive spongiosis is seen in 
FIP200 Nestin-Cre mice but not the Atg5 and Atg7 Nestin-Cre models. The variability 
observed between models will likely be accounted for by the stages at which autophagy is 
disrupted as well as non-autophagy functions for each target.  
 
To further delineate the function of autophagy in different neuronal types, targeted knockouts 
of Atg5 and Atg7 in Purkinje neurons of the cerebellum (Komatsu et al., 2006; Nishiyama et 
al., 2007), Atg7 in Agouti Related Peptide (AgRP) neurons of the hypothalamus (Kaushik et 
al., 2011), as well as Atg5 and Atg7 in Rhodopsin neurons of the retina (Chen et al., 2013; 
Zhou et al., 2015) have been developed. Deletion of Atg5 and Atg7 results in cell-
autonomous Purkinje neuron degeneration. The earliest signs of homeostatic disruption in 
these mice are Purkinje axonal swellings, which are observed prior to progressive dystrophy 
and degeneration of the axon (Komatsu et al., 2007b; Nishiyama et al., 2007). These 
findings support a key role of autophagy in axon homeostasis and highlight an early sign of 
neuronal dysfunction. Studies from cell culture systems have led to the proposal that 
different neuronal types may have varying capacities to degrade autophagy substrates, such 
as mutant polyglutamine proteins, and that this correlates with the sensitivity of that cell type 
to toxicity of aggregate-prone proteins. (Tsvetkov et al., 2013). 
 
In the peripheral nervous system (PNS), a specific role for autophagy in Schwann cell (SC) 
function has been identified during myelination and re-myelination.  In the early postnatal 
period when myelination is occurring, autophagy is involved in the maturation of SCs, 
particularly in the reduction of abaxonal cytoplasm volume. In conditional knockouts where 
ATG7 is absent in SCs, the abaxonal cytoplasm remains abundant and consequently small 
fiber hypermyelination is observed (Jang et al., 2015).  Conversely, autophagy upregulation 
via rapamycin treatment during the early post-natal period, leads to a greater reduction in 
abaxonal cytoplasm within the SCs. After nerve injury, myelin debris is cleared by SCs 
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through a newly described form of selective autophagy named, myelinophagy (Gomez-
Sanchez et al., 2015) and this debris clearance is delayed in Atg7-SC conditional knockouts 
(Jang et al., 2016). 
 
 
In addition to protecting against neurodegeneration, autophagy also regulates neurogenesis.  
An important role for autophagy in sustaining the post-natal pool of neural stem cells (NSCs) 
has recently emerged. In the adult brain, NSCs within the sub-ventricular zone (SVZ) of the 
lateral ventricle wall and subgranular zone (SGZ) of the dentate gyrus can produce new 
functional neurons in response to physiological and pathological stimuli (Gage, 2000). 
Ablation of FIP200 results in a reduced number of NSCs in the SVZ and the dentate gyrus, 
affecting the self-renewal capacity of NSCs (Wang et al., 2013a). Key autophagy proteins, 
including AMBRA1 and beclin 1, are highly expressed in the SVZ of adult mouse brain and 
heterozygosity for beclin 1 results in decreased cell proliferation in vitro (Yazdankhah et al., 
2014). Depletion of ATG5 in adult NSC in the dentate gyrus also leads to reduced survival 
and neuronal maturation (Xi et al., 2016). In all these studies, the depletion of the NSC pool 
could be attributed to apoptosis (Wang et al., 2013a; Xi et al., 2016; Yazdankhah et al., 
2014). However, although apoptosis is likely responsible for reduced survival of autophagy 
defective NSCs, it is unclear whether NSC differentiation and neuronal maturation is 
apoptosis-dependent (Xi et al., 2016; Yazdankhah et al., 2014). It will be interesting to 
examine whether potential beneficial effects of increasing basal autophagy act via changes 
in NSCs and this is likely to be an exciting topic for future research. In addition to effects on 
the stem cell pool, autophagy is required for normal neural progenitor cell proliferation and 
differentiation, as revealed by studies in ubiquitous ATG16L1 hypomorph mice and 
knockdown of ATG5 in vivo in embryonic brains (Lv et al., 2014; Wu et al., 2016). 
 
While impairment of autophagy is deleterious, autophagy upregulation appears to be 
protective in many normal contexts. Studies in C. Elegans have shown a clear association 
between increased longevity and constitutive autophagy, which may be mediated through 
multiple different but over-lapping mechanisms, including nutrient restriction (Hansen et al., 
2008), altered mitosis (Ghavidel et al., 2015) and mitochondrial turnover (Palikaras et al., 
2015). Similarly, pan-neuronal over-expression of Atg8a (Simonsen et al., 2008) or AMPK 
(Ulgherait et al., 2014) in Drosophila resulted in extended lifespan. Overexpression of ATG5 
in mice induces autophagy and extends lifespan, and is associated with anti-ageing 
phenotypes including leanness, increased insulin sensitivity and improved motor function 
(Pyo et al., 2013). In Huntington’s Disease (HD), expansion of the polyglutamine tract in the 
huntingtin (HTT) protein causes disease with a polyglutamine length-dependent severity.  In 
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mice where the polyglutamine expansion was removed from the endogenous Htt-coding 
gene, (delta-Q mice), an increase in autophagosome biosynthesis was observed and this 
was also associated with significantly longer lifespan.  (Zheng et al., 2010). Together, these 
studies indicate a beneficial effect of enhancing basal autophagy during aging.  
 
Neurodegenerative Diseases where Autophagy is  Impaired 
 
As outlined above, there is increasing evidence for the physiological importance of 
autophagy in neuronal health, raising the possibility that autophagy dysfunction may play a 
role in neurodegenerative diseases. Circumstantially, this is further supported by the major 
pathological phenotype of most late-onset neurodegenerative diseases, the presence of 
intraneuronal aggregates of misfolded proteins, which are substrates for autophagic 
degradation (Menzies et al., 2015a; Ravikumar et al., 2002). In some forms of disease, these 
aggregate-prone proteins are the result of specific mutations (such as in Huntington’s 
disesase). However, in the vast majority of diseases, the underlying reason for the presence 
of aggregates is unknown.  
 
For the most part, neurodegenerative diseases do not follow simple, monogenic inheritance 
patterns. However, in all major neurodegenerative diseases, a subset of cases are 
associated with inherited genetic mutations. These familial forms of disease allow an insight 
into the potential mechanisms of pathogenesis. Identification of disease-associated genes, 
and investigations into their functions, reveal that many impact autophagy. The absolute 
contribution of autophagy dysfunction to disease progression has yet to be established. 
Given that many neurodegenerative diseases are late-onset, it is possible that small 
alterations in the turnover of proteins will have cumulative effects that manifest later in life.  
 
The autophagy pathway is complex, with multiple steps and modes of regulation. This 
makes identifying potentially minor perturbations in the pathway difficult. Therefore, in some 
cases, the evidence for autophagy involvement in neurodegenerative disease pathogenesis 
appears controversial. This evidence is discussed in a disease-specific manner below (figure 
3). 
 
Alzheimer’s Disease 
The pathological hallmarks of Alzheimer’s Disease (AD) are intracellular tau tangles and 
extracellular Amyloid Beta (Aβ) plaques. Aβ is formed from Amyloid precursor protein (APP) 
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by two cleavage events. There is a complex interplay between Aβ and autophagy. Aβ may 
be degraded by autophagy and upregulation of autophagy has been shown to reduce Aβ 
levels in a number of systems (Boland et al., 2008; Spilman et al., 2010; Tian et al., 2011; 
Vingtdeux et al., 2011). However, Aβ may also be generated in autophagosomes, which 
appear to contain both APP and Presenilin-1 (PS-1), an enzyme involved in the cleavage of 
APP to Aβ (Boland et al., 2008; Yu et al., 2005). Furthermore, autophagy may play a role in 
the secretion of Aβ into the extracellular space, where it forms plaques, as deletion of ATG7 
in APP transgenic mice results in less Aβ extracellular secretion and plaque formation, 
contrary to what one may expect if autophagy simply degraded Aβ (Nilsson et al., 2013).  
 
Genetic studies have implicated	 Phosphatidylinositol Binding Clathrin Assembly Protein 
(PICALM) in Alzheimer’s disease (Harold et al., 2009; Jun et al., 2010) and changes in the 
level of this protein have been reported in the brains of patients with Alzheimer’s (Ando et 
al., 2013; Ando et al., 2016). PICALM is a clathrin adapter protein required for the 
endocytosis of SNAREs (Soluble NSF Attachment Protein Receptors) and loss of this 
function has been demonstrated to inhibit autophagy at multiple steps, including early 
autophagosome formation and maturation of autophagosomes (Moreau et al., 2014). Of 
course, altered trafficking of these SNAREs is also likely to impact upon other vesicle 
trafficking pathways and therefore, as with all of the disease mutations discussed in this 
review, it is yet to be established if, or how much, PICALM-mediated autophagy perturbation 
contributes to disease. However, a second mechanism through which PICALM function may 
impact on autophagy has also been proposed. Through its action in a complex with 
assembly polypeptide 2 (AP2), PICALM may act as an autophagy receptor, which is able to 
interact with LC3 and target APP into autophagosomes (Tian et al., 2013). 
 
Mutations in PS-1 cause familial AD, and there is a great deal of evidence demonstrating 
that these mutations change the way the APP protein is processed (for example (Citron et 
al., 1997). However, other functions of PS-1 may also contribute to disease pathogenesis. 
PS-1 has been shown to function as an ER chaperone for the V0a1 subunit of the lysosomal 
v-ATPase. Familial AD associated mutations in PS-1 result in decreased maturation of the 
lysosomal v-ATPase and thus increased lysosomal pH (Coffey et al., 2014; Lee et al., 2010; 
Wolfe et al., 2013), which would be predicted to reduce autophagosome clearance.   
Autophagy may also be affected by reduced levels of beclin 1 mRNA and protein, which 
have been reported in AD brains (Pickford et al., 2008; Small et al., 2005). Similarly, beclin 1 
protein levels are thought to be decreased due to caspase 3 cleavage, which is activated in 
the brains of AD patients (Rohn et al., 2011).  
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Tauopathies 
Tau accumulation into intracellular tangles is one of the hallmark pathologies of AD, and is 
also seen in a group of neuronal disorders termed tauopathies, which include progressive 
supranuclear palsy (PSP), corticobasal degeneration (CBD) and frontotemporal dementias 
(FTDs) (Lee et al., 2001). Hyperphosphorylated tau co-localizes with LC3-positive vesicles 
and the autophagy cargo-receptor p62/SQSTM1 in CBD and PSP patients (Piras et al., 
2016). Moreover, aberrant tau appears to disrupt axonal vesicle transport by impairing the 
dynein-dynactin complex, increasing the number of autophagosomes and contributing to 
tau-induced toxicity in FTDs and AD (Butzlaff et al., 2015; Majid et al., 2014). Tau has also 
been shown to bind lysosomal membranes and impair lysosomal permeability in vitro and in 
a mouse model of AD (Collin et al., 2014; Wang et al., 2009). Defective lysosomal 
membrane integrity was also found in AD patients (Perez et al., 2015) and more recently, 
increased levels of the lysosomal components LAMP1 (Lysosomal-associated membrane 
protein 1) and cathepsin D were reported in CBD and PSP patients (Piras et al., 2016).   
 
Parkinson’s Disease 
Compelling evidence supporting a role for dysfunctional autophagy as a causative factor in 
neurodegenerative disease comes from the studies of mitophagy in Parkinson’s Disease 
(PD). Autosomal recessive forms of early-onset PD are associated with mutations in genes 
encoding PINK1 (phosphatase and tensin homolog-induced putative kinase 1)  (Valente et 
al., 2004) and the E3 ubiquitin ligase, Parkin (Kitada et al., 1998).     Elegant studies have 
demonstrated that PINK1 and Parkin act in the same pathway to promote mitophagy. PINK1 
is stabilised on the outer membrane of damaged mitochondria, leading to the recruitment 
and activation of the E3 ubiquitin ligase, Parkin, on these mitochondria and ultimately their 
sequestration into autophagosomes (Matsuda et al., 2010; Narendra et al., 2008). This 
disease-associated mitophagy signalling pathway has been the subject of recent 
comprehensive reviews (Pickrell and Youle, 2015; Nguyen et al., 2016).  
 
Several models have been generated to elucidate the function of these mitophagy effectors 
in the nervous system. Although no gross behavioural changes were found in mice where 
Parkin was deleted (Goldberg et al., 2003; Itier et al., 2003; Perez and Palmiter, 2005; Von 
Coelln et al., 2004), the activity of striatal neuron mitochondria was impaired (Palacino et al., 
2004). A deficit in evoked dopamine release response and striatal synaptic plasticity in the 
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striatum was also observed (Kitada et al., 2009). Similarly, deletion of the Pink1 resulted in 
impaired respiration in striatal mitochondria and increased sensitivity to oxidative stress 
(Gautier et al., 2008). Furthermore, dopaminergic neurons derived from Pink1 or DJ-1 
knockout mice also showed defective morphology and reduced activity (Shim et al., 2011). 
Indeed, loss of endogenous Parkin synergises with a loss of DNA polymerase γ that results 
in increased mitochondrial mutations, to result in dopaminergic neuron damage (Pickrell et 
al., 2015). The use of a recently generated reporter mouse to assess in vivo mitophagy will 
shed light on how mitophagy flux is modulated in response to different genetic and 
pharmacological perturbations (Sun et al., 2015). 
 
Parkinson’s Disease (PD) is characterized by loss of dopaminergic neurons in the substantia 
nigra and typically by presence of α-synuclein (α-syn) inclusions. These inclusions have 
been shown to impact upon autophagy function (Tanik et al., 2013). In cells with α-syn 
inclusions, whilst lysosomal function appears normal, autophagosome maturation and fusion 
with the lysosomes is decreased, resulting in a decrease in protein degradation. It is 
interesting to note that this alteration in vesicle trafficking does not seem to result from a 
non-specific physical blockade of the axons by the inclusions, but rather a specific inhibition 
of endocytic and autophagic vesicles (Volpicelli-Daley	 et	 al.,	 2014). Independently of the 
formation of inclusions, increased levels of α-syn (as found in disease) has been shown to 
impair autophagy, as α-syn overexpression in cell and mouse models led to mislocalization 
of mATG9 (Winslow et al., 2010). Similarly, abnormal trafficking of mATG9 has been shown 
to be caused by the VPS35 (Vacuolar protein sorting-associated protein 35) D620N 
mutation, which causes an autosomal dominant form of PD. VPS35 is a component of the 
retromer complex which recruits	 the actin nucleation-promoting WASH (WASP and Scar 
homologue) complex to endosomes. D620N VPS35 prevents this recruitment and thus 
causes mATG9 mislocalisation and autophagy impairment (Zavodszky et al., 2014).  
 
The most common genetic risk factor for PD is heterozygosity for mutations in the lysosomal 
enzyme glucocerebrosidase (GBA).	These mutations have been reported in up to 31·3% of 
Ashkenazi Jewish patients with Parkinson’s disease, and up to 9·4% in patients of other 
ethnic origins (Sidransky and Lopez, 2012).  Homozygous GBA mutations cause the 
lysosomal storage disorder Gaucher disease (reviewed in Michel et al., 2016), where loss of 
GBA leads to the accumulation of its substrate, glucosylceramide within lysosomes and thus 
to autophagy impairment due to lysosomal dysfunction. In PD patients without GBA 
mutations, the levels and activity of the enzyme are decreased in brain areas with increased 
α-syn levels in early disease stages (Mazzulli et al., 2011; Murphy et al., 2014).  
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Loss of function mutations in the P-type ATPase, ATP13A2 (also known as PARK9), cause 
familial Kufor-Rakeb syndrome, characterized by early-onset Parkinsonism (Ramirez et al., 
2006). Lysosomal ATPases are required for the maintainance of lysosomal pH and therefore 
the activity of lysosomal proteases. Mutations in ATP13A2 impair these processes and lead 
to an increase in the number of autophagic vesicles, which are unable to fuse with 
lysosomes (Dehay et al., 2012). Impaired lysosomal degradative capacity in cells with 
ATP13A2 mutations leads to an accumulation of α-synuclein, which may contribute to the 
toxicity of ATP13A2 mutations. (Usenovic et al., 2012). Recent studies show that ATP13A2 
depletion leads to a decrease in the levels of another PD-associated gene, synaptotagmin 
11 (SYT11), and that it is this SYT11 decrease which causes lysosomal dysfunction and 
impaired autophagosome degradation resulting from loss of ATP13A2 activity. 
Overexpression of SYT11 in ATP13A2-knockdown cells is able to rescue the autophagy 
defects seen in these cells, demonstrating that they act in the same pathway (Bento et al., 
2016a).  
 
 
Polyglutamine disorders 
Nine neurological disorders are caused by mutant proteins with expanded glutamine repeats 
(polyQ), including Huntington's disease (HD), various spinocerebellar ataxias (SCAs) and 
spinal and bulbar muscular atrophy (SBMA). Autophagy perturbation is observed in several 
of these diseases. At the transcriptional level, mutant polyQ androgen receptor (that causes 
SBMA) interacts with transcription factor EB (TFEB), a potent autophagy gene inducer, and 
inhibits TFEB transactivation (Cortes et al., 2014). A transgenic mouse model of SCA3 
showed low levels of sirtuin 1 (Cunha-Santos et al., 2016), an enzyme that normally 
deacetylates several autophagy proteins to promote autophagy (Huang et al., 2015; Lee et 
al., 2008). Additionally, brains from mutant SCA3 transgenic mice have low levels of Parkin 
(Durcan et al., 2011), and beclin 1 (Nascimento-Ferreira et al., 2011). Beclin 1 appears to be 
sequestered into aggregates in the brains of mouse models of HD and SCA7 (Alves et al., 
2014; Shibata et al., 2006).  
 
The most investigated polyQ disease protein is huntingtin, mutated in HD.  Mutant huntingtin 
impairs efficient cargo recognition by autophagosomes (Martinez-Vicente et al., 2010), while  
wild-type huntingtin serves as a scaffold for the recruitment of several autophagy proteins 
during selective autophagy of targets, such as mitochondria and protein aggregates (Ochaba 
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et al., 2014; Rui et al., 2015). Furthermore, a role for huntingtin in axonal transport of 
autophagosomes has been suggested by live cell imaging studies in striatal neurons. 
Following either loss of huntingtin, or expression of the mutant protein, a decrease 
autophagosome transport and subsequent inhibition of substrate degradation was observed 
(Wong and Holzbaur, 2014a). Mutant huntingtin also interacts with and inactivates Rhes, a 
protein selectively expressed in the striatum, the brain region selectively affected in HD. 
Rhes is required for autophagy as it interacts with beclin 1 and reduces the inhibitory 
interaction of Bcl-2  with beclin 1 (Mealer et al., 2014). Another important autophagy 
negative regulator, mTOR, is sequestered to aggregates in HD and SCA7 brains (Alves et 
al., 2014; Ravikumar et al., 2004).  
 
In addition to potential mechanistic roles in autophagy, it has also been proposed that 
mutant huntingtin may accumulate due to the loss of an acetylation signal which would 
normal target it for degradation by this pathway (Jeong et al., 2009). Overall, mutant 
huntingtin is involved in different pathways that modulate autophagy - some are toxic and 
others which may be protective. The overall outcome in terms of autophagy activity may 
depend on the ratio of soluble to aggregated mutant protein.   
 
Amyotrophic Lateral Sclerosis 
ALS is associated with the accumulation of misfolded proteins such as SOD1 (Superoxide 
dismutase 1), TDP-43 (TAR DNA-binding protein 43), FUS (Fused in Sarcoma/Translocated 
in Sarcoma) and/or C9ORF72 (reviewed in Blokhuis et al., 2013). It is most commonly a 
sporadic disease but approximately 5-10% of cases are familial. A range of genes have 
been associated with the disease, but recently it has become apparent that a number of 
these genes encode for proteins that act as autophagy receptors, SQSTM1/p62 (Fecto et al., 
2011), OPTN (Maruyama et al., 2010) and Ubiquilin 2 (Williams et al., 2012), which enhance 
the incorporation of autophagy substrates into autophagosomes via interactions with LC3, as 
discussed above  (Khaminets et al., 2016). Mutations in SQSTM1/p62 have been associated 
with disrupted autophagic degradation of mutant SOD1 and TDP-43 (Gal et al., 2009; 
Teyssou et al., 2013). ALS-causing mutations in the LC3 binding region of SQSTM1/p62 
have been shown to impair its recruitment into autophagosomes (Goode et al., 2016). 
However mutations have been identified throughout the length of the protein and it is not 
clear how these mutations impact upon SQSTM1/p62 function. Similarly, disease-causing 
mutations in OPTN decrease autophagy and protein clearance (Shen et al., 2015) and also 
inhibit the ability of OPTN to recruit LC3 to damaged mitochondria and induce mitophagy 
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(Wong and Holzbaur, 2014b). OPTN also functions to bind LC3 and Myosin VI, which is 
required for the trafficking of autophagosomes (Tumbarello et al., 2012), the majority of ALS-
associated mutations in OPTN are located in the myosin VI-binding domain and show loss of 
this binding (Shen et al., 2015; Sundaramoorthy et al., 2015). Recently, mutations in TANK-
binding kinase 1 (TBK1) have been associated with ALS (Cirulli et al., 2015; Freischmidt et 
al., 2015), TBK1 has been shown to phosphorylate OPTN to promote efficient mitophagy 
and p62 to allow autophagosome maturation  (Moore	 and	 Holzbaur,	 2015;	 Pilli	 et	 al,	 2012). 
Disease-associated mutations in this kinase have been shown to reduce binding of TBK1 to 
OPTN and thus decrease the clearance of dysfunctional mitochondria (Richter et al., 2016).  
 
Alongside autophagy receptor proteins, other ALS-associated genes have been identified as 
having a role in autophagy. Disruption of the ESCRT machinery through mutations in 
charged multivesicular body protein 2B (CHMP2B) have been associated with both ALS and 
Frontotemporal Dementia, a neurodegenerative disease thought to be on a spectrum with 
ALS. Disease-associated mutations in CHMP2B impair autolysosome formation and lead to 
the accumulation of protein aggregates (Filimonenko et al., 2010; Lee et al., 2007).  
 
The most common cause of ALS is a hexanucleotide repeat expansion in the C9ORF72 
gene (DeJesus-Hernandez et al., 2011; Renton et al., 2011). These mutations may cause 
disease through a number of different mechanisms, including toxic gain-of-function from 
ATG-independent translation of the RNA repeats and loss of normal protein function (Todd 
and Petrucelli, 2016). A role has been suggested for C9ORF72 in endocytic vesicle 
trafficking and autophagy (Farg et al., 2014). Recently, C9ORF72 was found to form a 
complex with SMCR8 (Smith-Magenis Syndrome Chromosome Region, Candidate 8) and 
WDR41 (WD Repeat Domain 41) (Sellier et al., 2016; Sullivan et al., 2016). This complex 
acts as a GDP/GTP exchange factor (GEF) for the activation of Rab8 and Rab39, which are 
involved in the formation or maturation of autophagosomes (Pilli	et	al,	2012;	Seto	et	al.,	2013) 
and interacts with the autophagy receptors SQSTM1/p62 and OPTN (Sellier et al., 2016). 
Furthermore, C9ORF72 can interact with ULK1, a key kinase in the control of 
autophagosome formation and this interaction mediates the translocation of the ULK1 
autophagy initiation complex to the phagophore via RAB1a (Webster et al., 2016). 
Understanding the role of these genes in autophagy may be beginning to provide a link in 
pathogenic mechanism between ALS genes, as, for example, Rab8 has been identified as a 
modifier of toxicity in a Drosophila mutant CHMP2B model (West et al., 2015). Finally, 
another Rab GEF, Alsin (ALS2), has been associated with ALS (Yang et al., 2001). Alsin is 
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an activator of Rab5 (Topp et al., 2004), which has previously shown to regulate autophagy 
(Otomo et al., 2011; Ravikumar et al., 2008). 
 
Hereditary Spastic Paraplegia 
Hereditary spastic paraplegia (HSP) is a heterogeneous group of neurodegenerative 
diseases characterized by length-dependent degeneration of upper motor neuron axons 
resulting in progressive lower limb spasticity. To date, more than 70 distinct loci (SPG1-72) 
and 50 spastic paraplegia genes have been identified, the type of HSP is designated by the 
loci it is associated with (ie SPG1-56)(Fink, 2013). SPG11, encoding spatacsin, is the most 
prevalent gene mutated in autosomal recessive HSP. Spatacsin knock-out mice have a 
reduced number of lysosomes in Purkinje cells and impaired autophagic lysosome 
reformation in neurons (Varga et al., 2015). SPG11 and SPG15 (encoding spastizin) are 
both similar in their symptoms and in their cellular mechanisms; loss or mutation of either 
gene disrupts autophagosome maturation and lysosomal biogenesis (Chang et al., 2014; 
Renvoise et al., 2014). Spastizin also interacts with the beclin 1-UVRAG-Rubicon complex 
required for autophagosome maturation (Vantaggiato et al., 2013). 
 
A rare form of HSP is caused by mutations in TECPR2 (tectonin β-propeller containing 
protein 2) encoded by SPG49. The loss of TECPR2 results a reduction in levels of LC3, 
along with a reduction in lipidation of LC3 (Oz-Levi et al., 2012). TECPR2 contains an LC3-
interacting region (LIR) and its interaction with LC3 is required for maintenance of functional 
ER exit sites (Stadel et al., 2015). In patient fibroblasts with TECPR2 mutations, ER exit is 
inhibited and this loss is associated with decreased autophagosome formation.  
Lafora disease 
Lafora disease is a progressive neurodegenerative disease which manifests with myoclonus 
epilepsy caused by loss-of-function mutations in either malin or laforin, which form a 
complex. A characteristic feature of the disease is the formation of inclusions of insoluble 
forms of glycogen called polyglucosan bodies (or lafora bodies). As malin and laforin have 
been implicated in glycogen metabolism, it was originally assumed that perturbations in this 
function cause Lafora disease, but there is also clear evidence to support a key role for 
dysfunctional autophagy in this disease. Knockout mice for both genes show decreased 
LC3-II levels, and this is thought to result from increased mTOR activity in the case of 
mutations in laforin (Aguado et al., 2010; Garyali et al., 2014), although the mTOR 
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involvement is more controversial in the case of malin mutations (Criado et al., 2012; Garyali 
et al., 2014).  
 
Charcot-Marie-Tooth (CMT) disease 
CMT diseases are hereditary motor and sensory peripheral neuropathies caused by 
inherited mutations in genes encoding either myelin-related (CMT type 1, CMT1) or axonal 
(CMT type 2, CMT2) proteins (Bird, 1993a). CMT type 1 X-linked disease, one of the most 
common neurological disorders, is caused by loss-of-function mutations in the gene GJB1 
encoding the gap junction protein, connexin 32 (Bird, 1993b; Xie et al., 2016). Recent 
studies reported that connexin 32 depletion reduces autophagosome biogenesis, not via its 
gap junction function, but rather through directly interacting with autophagy core proteins 
(VPS34, BECN1, ATG16L1) to sequester them at the plasma membrane (Bejarano et al., 
2014). Upon starvation-induced autophagy, ATG14 localizes with a complex containing 
connexins and several autophagy proteins, facilitating the recruitment of ATG9 and 
formation of autophagosomes required for the degradation of connexins (Bejarano et al., 
2014). However, these data have not yet been validated in neurons or in the context of 
CMT1.  
 
The genes associated with the axonal CMT type 2 disease include those encoding the 
dynein-dynactin motor protein complex, also known to cause distal spinal and bulbar 
muscular atrophy (Puls et al., 2005; Punetha et al., 2015). Many of these mutations impact 
trafficking pathways relevant to autophagy. DYNC1H1 (dynein heavy chain 1) mutations, 
found in some familial cases of CMT2, directly affect neuronal retrograde axonal transport 
and phenocopy disease pathogenesis in rodent models (Weedon et al., 2011). Additionally, 
dynein mutations impair autophagosome-lysosome fusion by reducing the retrograde 
trafficking of autophagosomes to the microtubule organising centre where lysosomes are 
clustered. This causes reduced autophagic clearance and accumulation of the aggregate-
prone proteins (Jahreiss et al., 2008; Ravikumar et al., 2005). Other supportive evidence 
shows that mutations in the p150 subunit of dynactin cause motor neuron degeneration and 
result in protein aggregation (Levy et al., 2006). Additional genes affected in some cases of 
CMT2 encode endocytic-regulatory proteins, such as dynamin. Both knock-in mice bearing 
the dynamin 2 mutations (Durieux et al., 2012) and Drosophila models (Shi orthologue loss-
of-function) (Fang et al., 2016) showed accumulation of immature autophagosome structures 
due to defects in autolysosome acidification, rather than affecting the fusion step per se. 
Mutations in genes encoding proteins involved in endosomal maturation, such as RAB7, 
18	
	
lead to impaired autophagic flux (Ganley et al., 2011; Spinosa et al., 2008). A recent 
characterized CMT2 mutation in VCP (Valosin-containing protein) leads to a similar 
phenotype: accumulation of immature autophagosome and impaired autophagic flux 
(Gonzalez et al., 2014). 
 
Lysosomal Diseases 
Lysosomal diseases are rare, inherited disorders with variable phenotypes. They represent 
the most common cause of neurodegeneration in childhood but can also result in 
neurological impairment in adults (Poupetova et al., 2010; Wraith, 2002). Most lysosomal 
storage disorders are caused by loss-of-function of specific lysosomal hydrolases, leading to 
the accumulation of the substrates of these enzymes and accumulation of general 
autophagic substrates due to impaired autophagosome-lysosome fusion (Ballabio and 
Gieselmann, 2009; Platt et al., 2012; Settembre et al., 2008).  
 
There is increasing evidence that changes in membrane lipid composition as a result of 
lysosomal dysfunction contribute to lysosome fusion defects. In mouse models of 
Mucopolysaccharidosis Type III (Sanfilippo Syndrome), defects in the breakdown of heparin 
sulfate cause an altered membrane lipid composition, with SNARE protein redistribution 
resulting in impaired autophagosome-lysosome fusion and a block in autophagy (Fraldi et 
al., 2010; Settembre et al., 2008). The accumulation of the glycosphingolipid psychosine in 
Krabbe disease, caused by a defect of β-galactocerebrosidase, alters membrane lipid 
composition (Hawkins-Salsbury et al., 2013). In Niemann-Pick type A disease, where 
mutations in the gene encoding acid sphingomyelinase cause accumulation of 
sphingomyelin, defects of mATG9 trafficking and autophagosome closure have also been 
observed (Corcelle-Termeau et al., 2016). Sphingomyelin storage also leads to lysosomal 
membrane permeabilization, thereby liberating cathepsins into the cytosol (Serrano-Puebla 
and Boya, 2015).  
 
Apart from mutations in genes encoding lysosomal hydrolases, defects in posttranslational 
modifications, impaired trafficking of lysosomal enzymes or defective acidification also result 
in lysosomal dysfunction (Colacurcio and Nixon, 2016; Hirst et al., 2015; Kyttala et al., 2005; 
Morimoto et al., 1989; Tiede et al., 2005). One example is Multiple Sulfatase Deficiency in 
which a failed posttranslational modification of sulfatases by an ER resident enzyme 
abrogates the function of a whole group of lysosomal hydrolases (Dierks et al., 2009).  
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Beside this, impaired lysosomal structure, regeneration, fusion and signalling also contribute 
to lysosomal malfunction (Blanz et al., 2010; Chang et al., 2014; Cortes et al., 2014; Endo et 
al., 2015; Yu et al., 2010). For example, Niemann-Pick disease Type C, caused by loss of 
NPC1 function, leads to impaired Ca2+ homoeostasis and incorrect cholesterol trafficking 
with accumulation of unesterified cholesterol and glycosphingolipids in lysosomes and late 
endosomes, disrupting their fusion (Lloyd-Evans et al., 2008; Lloyd-Evans and Platt, 2010; 
Pacheco and Lieberman, 2008).  
 
Recently, the group of diseases associated with lysosomal dysfunction has expanded. 
Mutations in SNX14, a sorting nexin phosphoinositol binding protein localized on the late 
endosome and lysosomal membrane and involved in cargo sorting upon endocytosis, were 
found in patients with hereditary cerebellar ataxia. Autophagosome clearance was slowed in 
patient cells, suggesting lysosome-autophagosome dysfunction (Akizu et al., 2015). A 
specific role of the autophagosome-lysosome fusion for lysosomal disease pathology is 
underlined by the discovery of a missense mutation in VPS11 in patients with a rare form of 
leukoencephalopathy. VPS11 is a member of the HOPS (homotypic fusion and protein 
sorting) and CORVET (class C core vacuole/endosome tethering) complexes and mutations 
lead to impaired autophagy. A zebrafish VPS11 mutant (vps11(plt)) shows a reduction in 
CNS myelination and extensive neuronal death in the hindbrain and midbrain (Zhang et al., 
2016).  
 
Core autophagy genes implicated in neurodegenerative disease 
As outlined above, mutations in what might be termed “autophagy accessory” genes have 
been identified in a number of diseases, but diseases have also been identified which result 
from mutations in core autophagy genes. Recently an E122D ATG5 mutation was identified 
in two siblings with childhood ataxia characterized by lack of coordination and cerebellar 
hypoplasia (Kim et al., 2016). The E122D mutation weakens binding of ATG5 to ATG12 
resulting in decreased autophagosome formation and reduced autophagy flux. 
 
Another autophagy gene involved in disease is WDR45, a gene coding for the protein 
WIPI4, one of the four WIPI proteins (Proikas-Cezanne et al., 2004). WIPI proteins are key 
autophagic lipid sensors that facilitate autophagosome maturation by bridging PI(3)P 
production and LC3 lipidation in mammalian cells (Lamb et al., 2013). De novo mutations in 
WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood 
(SENDA) (Haack et al., 2012; Saitsu et al., 2013), also called BPAN (beta-propeller protein-
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associated neurodegeneration). In lymphoblastoid cell lines derived from BPAN patients, 
mutant WDR45 is less stable and degraded, resulting in decreased protein levels compared 
to unaffected individuals. These cells showed an impairment in autophagy flux and an 
accumulation of LC3-positive autophagosome membranes (Saitsu et al., 2013). CNS-
specific WDR45 knockout mice exhibit some aspects of the BPAN phenotype: poor motor 
coordination, impaired learning and memory, and extensive axon swelling with numerous 
axon spheroids, along with autophagy perturbation in the form of accumulation of p62 and 
ubiquitin positive aggregates (Zhao et al., 2015). 
 
Autophagy therapeutics for Neurodegenerative diseases 
	
The neuropathology of protein misfolding diseases is intimately linked with the propensity of 
specific proteins to misfold and self-associate, giving rise to an array of oligomers and 
aggregates. As many of these proteins cause disease primarily via toxic-gain-of function 
mechanisms, one way of combatting disease is to reduce the levels of such proteins 
(Ciechanover and Kwon, 2015). Furthermore, most aggregate-prone, neurodegenerative 
disease-associated proteins have been shown to be autophagy substrates, including mutant 
huntingtin, alpha-synuclein, and tau (Berger et al., 2006; Ravikumar et al., 2002; Ravikumar 
et al., 2004; Webb et al., 2003); (Rubinsztein et al., 2012). Importantly, induction of 
autophagy reduces the levels of both the soluble and aggregated species in such models, 
and is associated with beneficial effects. It is likely that the autophagic process is capturing 
small oligomeric species and not the very large aggregates visible by light microscopy  - the 
reduction of the large aggregates after autophagy induction may reflect a reduced input of 
the smaller species into the aggregates and the flux of the mutant proteins on and off the 
aggregates (Berger et al., 2006; Ravikumar et al., 2002; Ravikumar et al., 2004; Webb et al., 
2003). 
 
Many small molecules employed to induce autophagy have an impact on cellular effectors 
with pleiotropic effects, such as mTOR and AMPK (Fleming et al., 2011; Levine et al., 2015). 
Nevertheless, in many cases, the impact of such autophagy modulators on the levels of the 
substrates have been shown to be autophagy-dependent (e.g.Williams et al., 2008). 
Supplementary table 1 lists key autophagy enhancing molecules that have been validated in 
vivo, their mechanism of action, biological targets and CNS penetration profiles.  
 
Autophagy inducers can be classified into two main groups; those acting via mTOR-
dependent or mTOR-independent targets. mTOR inhibitors are either ATP competitive 
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inhibitors (e.g. Torin1 and related compounds) or non-ATP competitive inhibitors (e.g. 
rapamycin and rapalogs) (Kim and Guan, 2015). Due to their inhibition of mTORC1, 
mTORC2 and in some cases of PI3K activities, chronic dosing of ATP-competitive inhibitors 
of mTOR activity in animals present significant toxicity issues (Kim and Guan, 2015) and for 
this reason they are generally unsuitable for studies in mouse models of neurodegeneration, 
which typically require chronic dosing. While mTORC1 inhibits autophagy, mTORC2 is 
required for autophagy and the autophagy inhibition resulting from prolonged exposure to 
such compounds may explain at least some of their toxicity in vivo (Renna et al., 2013). 
Rapamycin and rapalogues have relatively safer profiles owing to their non-ATP competitive 
mode of action and apparent selectivity for mTORC1 (Wander et al., 2011), allowing 
everolimus (a rapalogue; (Lebwohl et al., 2013) to be recently approved by the FDA for the 
treatment of tuberous sclerosis. Rapamycin and its analogues have shown benefits as 
autophagy inducers in animal models of AD, PD, FTD, HD and PrP (Cortes et al., 2012; 
Jiang et al., 2014; Menzies et al., 2010; Ozcelik et al., 2013; Ravikumar et al., 2004; Sarkar 
et al., 2008; Spilman et al., 2010; Wang et al., 2013b). The therapeutic efficacy of rapamycin 
in SOD1 ALS mouse models is complex, with some studies reporting detrimental effects 
(Zhang et al., 2011) and others reporting beneficial effects only after uncoupling of it’s 
immunomodulatory function (Staats et al., 2013).  
 
Many mTOR-independent autophagy activators signal via AMPK. Trehalose, a widely 
studied autophagy inducer in neurodegeneration models (Sarkar et al., 2007), has recently 
been characterized as acting via AMPK activation (DeBosch et al., 2016). The molecular 
targets of this disaccharide have been proposed to be GLUT proteins, a family of glucose 
transporters whose inhibition by trehalose results in AMPK activation (DeBosch et al., 2016). 
Trehalose dosing in mice has shown therapeutic effects, concomitant with autophagy 
induction, in an impressive variety of mouse models of neurodegeneration including AD, PD, 
FTD, HD, SCA17, PrP, ALS, and OPMD (Aguib et al., 2009; Castillo et al., 2013; Chen et al., 
2015; Davies et al., 2006; Du et al., 2013; Li et al., 2015; Rodriguez-Navarro et al., 2010; 
Schaeffer and Goedert, 2012; Schaeffer et al., 2012; Tanaka et al., 2004; Tanji et al., 2015; 
Zhang et al., 2014). 
 
Metformin is another AMPK-dependent autophagy inducer which has shown beneficial 
effects in animal models of neurodegeneration. Metformin has shown efficacy in animal 
models of AD, HD and Lafora disease (Berthier et al., 2016; Ma et al., 2007; Son et al., 
2016) but showed no efficacy in ALS models (Kaneb et al., 2011). Berberine, which showed 
efficacy in an HD model (Jiang et al., 2015), may also induce autophagy via AMPK activation 
(Yu et al., 2014). Methylene blue, a reported anti-aggregant and AMPK activator (Shin et al., 
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2014), was shown to induce autophagy and ameliorate disease phenotype in FTD models 
(Congdon et al., 2012; Hochgrafe et al., 2015; Melis et al., 2015). Nilotinib, a c-Abl kinase 
inhibitor and AMPK activator (Yu et al., 2013), was shown to induce autophagy and 
ameliorate disease phenotype in PD mice (Hebron et al., 2014; Lonskaya et al., 2015).  
 
Finally, a growing number of autophagy inducers are being characterized which may act on 
other pathways, including compounds acting on the modulation of cAMP/IP3, such as 
rilmenidine, clonidine, minoxidil and verapamil, which have been shown to ameliorate 
phenotypes in animal models of HD (Rose et al., 2010; Williams et al., 2008) 
(Supplementary table 1).  
 
In addition to the small molecules with in vivo validation reviewed above, there are further 
molecules which have been shown to be active in cell-based models but not yet in vivo. 
These are presented, with their mechanism of action and any available evidence for 
potential CNS penetration in supplementary table 2. 
 
Non-small molecule approaches 
In addition to small molecule therapeutics, a number of other strategies for autophagy 
enhancement have been adopted. Shoji-Kawata et al. have reported the development of a 
Tat-beclin 1 peptide, which consists of the HIV-1 Tat protein transduction domain linked to a 
modified 18 amino acid sequence based on the residues 267-284 of beclin 1 (Shoji-Kawata 
et al., 2013) This region was identified as being required for the autophagy-inducing effects 
of beclin 1. The Tat-beclin 1 peptide was found to increase autophagic flux via the canonical 
pathway using a range of cell models and to decrease the number of small huntingtin 
aggregates in HeLa cells. It was also shown that Tat-beclin 1 increased GFP-LC3 dots in a 
range of tissues in a transgenic mouse model (Shoji-Kawata et al., 2013). 
 
A number of mouse studies exploring the potential of gene therapy have been reported. For 
example, delivery of the TFEB gene ameliorates signs of disease in a PD model based on 
adeno-associated virus (AAV) vector-mediated over-expression of human wild-type α-
synuclein in the rat midbrain (Decressac et al., 2013) and in a transgenic mouse model 
overexpressing tau, TFEB was able to decrease levels of pathological tau and improve 
cognitive performance and synaptic function (Polito et al., 2014).  Beneficial effects have 
also been reported with beclin-1 over-expression in an α-synuclein model of PD/Lewy Body 
Diseases (Spencer et al., 2009), and in a model of Machado-Joseph disease (Nascimento-
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Ferreira et al., 2011). Parkin overexpression has beneficial effects in an AD model 
(Khandelwal et al., 2011). 
 
Another possible candidate target for such approaches is calpain. Knockdown of calpain in 
an Huntington’s disease Drosophila model (RNAi) results in upregulation of autophagy, 
reduction of huntingtin aggregate number and increases cell survival and is also protective 
against tau toxicity in HD and tauopathy models, respectively (Menzies et al., 2015b).  In 
mice, neuronal overexpression of calpastatin (CAST), an endogenous inhibitor of calpain, 
increased autophagy and confers protection when crossed to HD mice, improving aggregate 
burden, behavioural measures of degeneration and long-term survival (Menzies et al., 
2015b). These CAST transgenic mice were compared to wild-type littermates and no deficits 
were found by SHIRPA behavioural testing or on survival, suggesting that such a strategy 
may be well tolerated.  
 
Considerations for autophagy as a therapeutic strategy in 
neurodegeneration 
	
Taken together, the evidence from pharmacological efficacy mouse studies suggests 
that autophagy activation has significant therapeutic potential across a wide range of 
neurodegenerative diseases. Whilst the majority of studies of autophagy modulating 
approaches in neurodegenerative disease models have reported beneficial effects on 
disease signs, this is not universally true (Hernandez et al., 2012; Komatsu et al., 2007). For 
example, in the SOD1 G93A mutant model of ALS, treatment with rapamycin decreased 
lifespan and increased motor neuron degeneration (Zhang et al., 2011). However, rapamycin 
is protective in such mice lacking mature lymphocytes, suggesting that the 
immunosuppressive effects of this drug (unrelated to autophagy) may be deleterious in this 
disease and may counterbalance protective effects of autophagy induction  (Staats et al., 
2013). Indeed, an alternative mTOR-independent autophagy inducer, trehalose, is protective 
in this SOD1 ALS model (Zhang et al., 2014). 
 
Similarly the time-point in disease at which autophagy is induced may be critical. For 
example, many studies have demonstrated the protective effect of autophagy upregulation 
on α-synuclein toxicity (eg Decressac et al., 2013, Hebron et al., 2014, Spencer et al., 2009). 
However, at least in tissue culture, α-synuclein aggregate-containing cells appear to have 
impaired autophagosome maturation, and autophagy upregulation may actually be toxic 
under these conditions (Tanik et al., 2013). Likewise, the point of intervention in the 
24	
	
autophagy pathway might be an important consideration. For example where 
autophagosome clearance or degradation is impaired, upstream induction of autophagy may 
lead to a largely unproductive accumulation of autophagosomes, possibly leading to toxic 
consequences, this may be avoided by more directly targeting lysosomal function or using 
approaches that enhance the entire pathway, including increasing lysosomal capacity (for 
example with TFEB, as discussed above). Thus, one should ideally understand autophagy 
dynamics in diseases one is aiming to treat in order to best tailor the therapeutic approach to 
the most suitable diseases. Further developments in autophagy-based therapeutics for 
neurodegeneration must await the advent of sharper pharmacological tools for autophagy 
induction, with more selective molecular targets within the autophagic process, and of higher 
resolution readouts for different steps of the autophagic flux with which autophagy 
dysfunction in different neurodegenerative diseases can be profiled. 
 
Conclusions 
	
In this review, we have highlighted how autophagy defects at various stages of the pathway 
may be seen in diverse neurodegenerative conditions, and that autophagy upregulation may 
be a promising therapeutic strategy for some diseases. However, the roles of autophagy in 
health and disease may be more complex and not simply cell-autonomous. For example, 
autophagy impacts inflammatory and immune processes, which are increasingly being 
implicated in various neurodegenerative diseases (Rubinsztein et al., 2015). Future studies 
aiming to understand non-cell autonomous effects of autophagy in the nervous system and 
its relevance to neuronal-glial interactions are likely to be informative.  
 
From a therapeutic perspective, we believe that autophagy is a promising target mechanism. 
In many cases, it enhances the removal of the primary toxic entity causing disease (e.g. 
mutant tau or mutant huntingtin), and thus targets such diseases at their roots. Autophagy 
upregulation also has additional protective effects by reducing susceptibility to pro-death 
insults (Boya et al., 2005; Ravikumar et al., 2006). One benefit of autophagy upregulation as 
a therapeutic approach is that one need not require constitutive activation of the pathway, as 
a pulsatile strategy (like periodically taking out the rubbish) may be sufficient to have 
efficacy, especially if employed over a long time period. This would have major benefits from 
a drug toxicity perspective. 
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Figure Legends: 
 
Figure 1. Overview of the mammalian autophagy pathway. Nutrient depletion, growth factors 
deprivation and low energy are well established autophagy inducers. These culminate in mTORC1 
inhibition and AMPK activation, which, in turn, positively regulate the ULK1 complex through a series 
of phosphorylation events. Induction of the ULK1 complex subsequently activates the VSP34 
complex, which leads to PI(3)P synthesis in pre-autophagosomal structures – the membrane of these 
structures, appear to have multiple sources, such as the endoplasmic reticulum, Golgi apparatus and 
trans-Golgi network, plasma membrane, endosomal compartment and mitochondria. PI3P defines the 
LC3-lipidation sites for autophagosome precursors by assisting in the recruitment of the ATG12-
ATG5-ATG16L complex. This complex is essential for the conjugation of LC3-I to PE in membranes, 
which sustains membrane elongation and engulfment of a variety of substrates (e.g. protein 
aggregates, infectious agents and damaged mitochondria) that end up being degraded in the 
lysosome after fusion with autophagosomes. Conditions characterized by mTORC1 inactivation are 
also accompanied by translocation of TFEB to the nucleus and TFEB activation, leading to the 
transcription of many autophagy and lysosomal genes, which ensure synthesis of key components of 
the pathway and efficient autophagy-dependent degradation. AMPK, AMP-dependent protein kinase; 
mTORC1, mammalian target of rapamycin complex 1; PE, phosphatidylethanolamine; PI3P, 
phosphatidylinositol 3-phosphate; TFEB, transcription factor EB; ULK, mammalian homologs of the C. 
elegans uncoordinated-51 kinase.  
Figure 2. Autophagy regulation in response to nutrients. The key signalling pathway controlling 
autophagy response to nutrient and energy levels converges on the phosphorylation of the ULK1/2 
complex at different sites. This phosphorylation regulates the recruitment of the VPS34 complex to 
the phagophore and hence the production of PI3P and downstream autophagy effectors via the 
binding of WIPI proteins. 
Figure 3. Intersections between autophagy and disease associated genes. An increasing 
number of genes associated with neurodegenerative diseases have now been implicated in 
autophagy function. These genes act at a number of different steps throughout the autophagic 
process, from early steps of autophagosome formation through to autolysosome formation. In the 
diagram above their proposed site of action is indicated, along with the neurodegenerative disease 
with which they are associated. 
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Table S1. Autophagy enhancers with validation in vivo. 
Autophagy Enhancer Autophagy in vivo Other properties 
Compound Mechanism Target Effect Model Ref CNS 
penetrante 
Ref Comments 
 
AMPK 
activation SLC2A Induction 
AD (APP/PS1) Du, et al., 2013 
Yesa {Tanaka, 2004 #979} 
Dietary 
supplement 
PD (A53T SNCA) Tanji et al. 2015  
HD (R6/2) Tanaka et al., 2004 
ALS (SOD1) Castillo et al. 2013; Li et al., 2015; Zhang et al., 2014  
Prion (PrPsc) Aguib et al., 2009 
SCA17 Chen et al., 2015 
OPMD Davies et al., 2006 
 
mTOR inhibitor mTORC1 Induction 
AD (PDAPP) Spilman et al., 2009; Pierce et al., 2013 
Yesa {Ozcelik, 2013 #994} 
Approved for the 
prophylaxis of 
organ rejectionf 
PD (A53T SNCA) Bai et al., 2015 
FTD (TDP-43) Wang et al., 2013 
FTD (TAU P301S) Ozcelik et al., 2013 
FTD (TAUP 301L)  Siman et al., 2015 
ALS (SOD1 G93A) Staats et al., 2013 
Prion (PrP A116V) Cortes et al., 2012 
 
AMPK 
activation AMPK Induction 
AD (Tg6799) Son et al., 2016 
Yesa Labuzek et al. 2010 
Approved for non-
insulin-dependent 
diabetes mellitusf 
ALS (SOD1 G93A) Kaneb et al., 2011 
HD (R6/2) Ma et al., 2007 
 
AMPK 
activation 
Other (anti-
aggregant) 
MAO 
inhibitor 
Induction 
FTD (2N4R Tau-
ΔK280) Hochgrafe et al., 2015 
Yesa Peter et al., 2000 
Investigational 
inhibitor of Tau 
protein 
aggregationf ALS (SOD1, TDP-
43) Audet et al., 2012 
 
AMPK 
activation 
c-ABL 
inhibitor Induction 
AD (TgAPP) Lonskaya et al., 2013a 
Poora Reinwald et al., 2014 
Approved 
leukemia 
treatmentf 
PD (A53T SNCA) Hebron et al., 2013b 
 
cAMP/IP3 IMP inhibitor Induction 
AD (APP/PS1) Zhang et al., 2011 
Yesa Wraae, 1978 
Approved for 
bipolar 
disorder/epilepsyf 
ALS (SOD1 G93A)  Fornai et al., 2007 
ALS (SOD1 G93A) Gill et al., 2009 
ALS (SOD1 G93A) Pizzasegola et al., 2009 
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mTOR 
activation 
Other 
(Unknown) Suppression ALS (SOD1 G93A) Hsueh et al., 2016 
NDc 
(TPSA = 26.3 
Å2; MW = 
188.2) 
 Noned Investigational probe 
 
Other Other (HDAC1/3) Induction HD (N171-82Q) Jia et al., 2012 Poor
a Beconi et al., 2012 
Investigational 
probe 
 
AMPK 
activation 
Other (α-
glucosidase 
inhibitor, 
stimulation 
of 
glycolysis) 
Induction HD (N171-82Q) Jiang et al., 2015 Yesa Wang et al., 2005 Traditional Chinese medicine 
 
Other 
Other 
(NHR 
agonist) 
Induction ALS (SOD1 G93A) Kim et al., 2013 Yesa Uhr et al., 2002 
Approved 
progesterone 
supplementation 
or replacementf 
 
Other 
Other 
(sirtuin 
inhibitor) 
Induction AD (3xTG) Liu et al., 2013 Yesa Hankes et al., 1991 
Approved for 
blacktongue and 
pellagraf 
 
Other 
Other 
(MTMR14 
inhibitor) 
Induction HD (Drosophila) Billes et al., 2016, Papp et al., 2016 Yesa Papp et al., 2016 Investigational probe 
 
mTOR 
activation 
Other 
(Unknown) Suppression AD (APP/PS1) Wei et al., 2014 
NDc 
(TPSA = 87.3 
Å2; MW = 
327.3) 
 Noned Investigational probe 
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mTOR inhibitor 
Other (Na 
Channel 
inhibitor) 
Induction AD (APP/PS1) Li et al., 2013 Yesa Fortuna et al., 2013 
Approved 
anitepilepticf 
 
cAMP/IP3 
Other 
(imidazolin
e receptors 
agonist) 
Induction HD (N171-82Q) Rose et al., 2010 Yesa Montastruc et al., 1989 
Approved 
treatment for 
hypertension 
(Remková et al., 
2002) 
 
cAMP/IP3 
Other (α2-
receptors 
agonist) 
Induction HD (Drosophila and Zebrafish) Williams et al., 2008 Yes
a Castro et al., 1989 
Approved 
centrally-acting 
anti-hypertensivef 
 
cAMP/IP3 
Other 
(Potassium 
channel 
agonist ) 
Induction HD (Drosophila and Zebrafish) Williams et al., 2008  Yes
g Nagendra et al., 2003 
Approved 
treatment for 
androgenic 
alopecia and 
hypertensionf 
 
cAMP/IP3 
Other 
(voltage-
dependent 
calcium 
channels 
inhibitor ) 
Induction HD (Drosophila and Zebrafish) Williams et al., 2008 Yes
b Narang et al., 1988 
Approved class IV 
anti-arrhythmia 
agentf 
 
 
rifampicin 
mTOR 
inhibition 
Other 
(PP2A) Induction AD (Tg2576) Umeda et al., 2016 Poor
a Shobo et al., 1998 
Approved braod 
spectrum 
antibacterial for 
tuberculosisf 
aCompound detected in brain or CSF during in animal studies; bcompound detected in CSF during clinical studies; cefficacious in animal models of CNS disorders but no 
direct measurement of compound in the brain; dto the authors’ knowledge there have been no reported studies which have directly measured levels of these compounds in 
CSF or brain tissue; ewhere experimental CNS penetration data are not available, calculated total polar surface area (TPSA) and molecular weight (MW) are provided as 
predictors of brain penetration (likelihood of being a Pgp substrate increases where TPSA > 60 Å2 and MW > 400; Rankovic, 2015); finformation obtained from 
www.drugbank.ca; gmixodinil has been studied in models where the blood-brain barrier is impaired and is known to increase brain penetration through modulation of 
potassium channels. 
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Table S2. Selected autophagy enhancers with in vitro activity. 
Autophagy enhancers with in vitro activity Other properties 
Compound Mechanism Reference CNS penetrante CNS ref comments 
 
mTOR inhibition 
Balgi et al., 2009 Yesa Zhang et al., 2007 Investigational probe 
 
Balgi et al., 2009  ND (TPSA = 101.1, MW = 327.1)  None
d Approved for the treatment of tapeworm infectionsf 
 
Thoreen et al., 2009  Yesc  Vogel et al., 2015 Investigational probe 
 
Balgi et al., 2009  Yesb Singlas et al., 1978 Approved CPT-1 and CPT-2 inhibitor for angina pectorisf 
 
Reduction of 
intracytosolic Ca2+ 
levels 
Williams et al., 2008 Yesa Heffez et al., 1985  
Ca2+ channel blocker; 
adjunct to improve 
neurologic outcome 
following subarachnoid 
hemorrhagef 
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Balgi et al., 2009 Poorb Broekhuysen et al., 1969 
Approved class III 
antiarrhythmic agentf 
 
Williams et al., 2008  Yesa Doran et al., 2005 
Approved non-selective 
calcium channel blocker  mu 
opioid receptor binder for 
diarrheaf 
 
Zhang et al., 2007  Yesa  Soudijn et al., 1972 
Approved antipsychotic; 
blocks dopamine and various 
other receptorsf 
 
unknown Sarkar et al., 2007 
 ND 
(TPSA = 58.7, MW = 267.3)  None
d Investigational probe 
 
 ND 
(TPSA = 49.3, MW = 253.3)  None
d Investigational probe 
 
ND 
(TPSA = 36.7, MW = 264.1)  None
d Investigational probe 
 
Calpain inhibitor Williams et al., 2008  Yesc Wei et al., 2015 Investigational probe 
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upregulation of 
autophagosome 
synthesis 
Vicinanza et al., 2015  ND (TPSA = 256.0, MW = 967.1)  None
d 
Endogenous lipid which 
sustains noncanonical 
autophagy in PI(3)P-depleted 
cells (Vicinanza et al., 2015) 
 
reduction of 
Ins(1,4,5)P3 levels Williams et al., 2008  Yes
a  Cornford et al., 1985 
Approved treatment for 
epilepsy & bipolar disorderf 
 
reduction of cAMP 
levels 
Williams et al., 2008  ND (TPSA = 615.1, MW = 1505.1)  None
d Investigational probe 
 
Williams et al., 2008  ND
 
(TPSA = 95.8, MW = 235.3)  None
d 
Adenyl cyclase inhibitor; not 
an approved drug (Williams 
et al., 2008) 
 
AMPK activation Parikh et al., 2010  Predicted to be poorg Sierra et al., 2011, Lennernas, 2003 
Approved lipid lowering 
treatment. Depletes 
geranylgeranyl diphosphate 
and activates AMPKf 
 
TFEB activation Chauhan et al., 2015 Predicted to be poor Wiser et al., 2008 
Mucolytic agent used in the 
treatment of respiratory 
disorders 
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mTOR inhibitor Chauhan et al., 2015 Yes Tellez-Giron et al., 1984 Antihelmintic 
aCompound detected in brain or CSF during in animal studies; bcompound detected in CSF during clinical studies; cefficacious in animal models of CNS disorders but no 
direct measurement of compound in the brain; dto the authors’ knowledge there have been no reported studies which have directly measured levels of these compounds in 
CSF or brain tissue; ewhere experimental CNS penetration data are not available, calculated total polar surface area (TPSA) and molecular weight (MW) are provided as 
predictors of brain penetration (likelihood of being a Pgp substrate increases where TPSA > 60 Å2 and MW > 400; Rankovic, 2015); finformation obtained from 
www.drugbank.ca; gIn vitro studies, atorvastatin is also a known Pgp substrate;  
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